Skip to Content
 

News: Immunotherapy

Immunotherapies linked to specific heart complications

Tuesday, November 20th, 2018

Cardiovascular complications linked to immune checkpoint inhibitors include myocarditis, pericarditis, vasculitis and arrhythmias and occur early in the course of treatment, Vanderbilt researchers report.

Team’s findings show glutamine metabolism affects T cell signaling

Monday, November 5th, 2018

A drug currently in clinical trials as an anticancer agent might also be useful as a treatment for inflammatory and autoimmune diseases. The findings also suggests strategies for using the drug to enhance cancer immunotherapies.

Combination therapy improves small-cell lung cancer survival

Friday, October 26th, 2018

Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.

Study tracks incidence, timing of immunotherapy-related deaths

Thursday, September 13th, 2018

Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.

Cancer immunotherapy drugs linked with more serious heart effects

Monday, March 12th, 2018

Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.

Research conducted by medical students recognized at events

Monday, March 12th, 2018

Vanderbilt-Ingram Cancer Center, Meharry Medical College and Tennessee State University Cancer Partnership recently hosted the 2018 annual retreat and poster contest, “Health Disparities in Cancer Immunology & Immune Therapy.”

Study to test combination therapy for breast cancer

Friday, October 27th, 2017

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR T therapy

Wednesday, October 25th, 2017

Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.

STINGing combination for cancer

Thursday, June 22nd, 2017

Cyclic dinucleotides (CDNs) are intracellular messengers produced in bacteria that can bind to and activate an immune-mediated signaling cascade called STING in mammalian cells. CDNs have shown antitumor activity in melanoma and breast tumors. Reporting this month in the journal Head & Neck, Young J. Kim, M.D., Ph.D., associate professor of Otolaryngology at Vanderbilt University, […]

Pow! Unleashing immunotherapies & protecting patients

Wednesday, May 31st, 2017

The television ad opens on a city skyline at sunrise, with people looking up curiously at the buildings. “It’s not every day something this big comes along,” says the narrator, as words appear projected on the side of a building. “A chance to live longer,” the words spell out in big, bright capital letters. The […]

Next Page »« Previous Page